Pharmaceutical

Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics’s CTX-131?

CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Cervical Cancer;Endometrial Cancer.

Dec 15, 2024 - 06:00
CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Cervical Cancer;Endometrial Cancer.
Read the original article

Tags:

Previous Article

Carisma to undergo staff and clinical candidate restructuring to stretch cash re...

Next Article

Risk adjusted net present value: What is the current valuation of Forte Bioscien...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Addressing industry challenges through flexible, personalized eCOA solutions

Addressing industry challenges through flexible, person...

Aug 9, 2024

FDA budget battles, prisons’ sobering Covid response & BIO’s CEO search is on

FDA budget battles, prisons’ sobering Covid response & ...

May 23, 2023

STAT+: Top Senate Republican signals interest in site-neutral reform for hospitals

STAT+: Top Senate Republican signals interest in site-n...

Jun 8, 2023